Sheehan syndrome – not a mystery anymore
More details
Hide details
1
Students’ Scientific Club, Department of Pathophysiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
2
Department of Pathophysiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Corresponding author
Dariusz Szczuraszek
Studenckie Koło Naukowe, Zakład Patofizjologii, ul. Jordana 19, 41-800 Zabrze
Ann. Acad. Med. Siles. 2026;80:92-97
KEYWORDS
TOPICS
ABSTRACT
Sheehan syndrome is a condition of postpartum failure or complete necrosis of the pituitary gland in women, caused by a postpartum hemorrhage. It is most often chronic and reveals itself many years after delivery. Women develop pituitary insufficiency as a result of postpartum hemorrhage, leading to a deficiency of one or more pituitary hormones. Sheehan syndrome is rare, and its diagnosis and course are influenced by the quality of obstetric care provided. Frequent growth hormone deficiency causes metabolic complications, e.g., lipid profile abnormalities or insulin resistance. The disease also affects the mental health of patients, reducing quality of life. The basic form of treatment is pharmacological supplementation of the deficient hormones. Sheehan syndrome is an increasingly recognizable disease which – properly diagnosed and treated – will not significantly affect the patient’s health. An essential adverse factor is late diagnosis, which reduces the effectiveness of treatment and risks the development of serious complications. Articles about Sheehan syndrome, postpartum hemorrhage and pituitary insufficiency were searched in the PubMed database using following keywords in English: “Sheehan syndrome,” “treatment,” “pituitary dysfunction,” “hemorrhage,” “postpartum hemorrhage,” and “cardiovascular.” Materials from the library collection of the Medical University of Silesia Faculty of Medical Sciences in Zabrze were also used. The purpose of this article is to summarize the current state of knowledge about Sheehan syndrome in terms of its epidemiology, etiology, treatment methods, and complications.
REFERENCES (39)
1.
Makharia A, Lakhotia M, Tiwari V, Gopal K. Recurrent hypoglycaemia and dilated cardiomyopathy: delayed presentation of Sheehan’s syndrome. BMJ Case Rep. 2021;14(6):e242747. doi: 10.1136/bcr-2021-242747.
2.
Karaca Z, Kelestimur F. Sheehan syndrome: a current approach to a dormant disease. Pituitary. 2025;28(1):20. doi: 10.1007/s11102-024-01481-1.
3.
Federspiel JJ, Eke AC, Eppes CS. Postpartum hemorrhage protocols and benchmarks: improving care through standardization. Am J Obstet Gynecol MFM. 2023;5(2S):100740. doi: 10.1016/j.ajogmf.2022.100740.
4.
Manna S, Chakrabarti SS, Gautam DK, Gambhir IS. Sheehan syndrome with Gitelman syndrome, Tackling Additive Morbidity. Iran J Kidney Dis. 2019;13(6):417–418.
5.
Du GL, Liu ZH, Chen M, Ma R, Jiang S, Shayiti M, et al. Sheehan’s syndrome in Xinjiang: Clinical characteristics and laboratory evaluation of 97 patients. Hormones (Athens). 2015;14(4):660–667, doi: 10.14310/horm.2002.1624.
6.
Dourado MLBF, Costa TPD, Carvalho MS, Moura CGG. Dilated Cardiomyopathy Reversibility in Sheehan’s Syndrome: A Case Report. Arq Bras Cardiol. 2021;116(2 Suppl 1):17–20. doi: 10.36660/abc.20190547.
7.
Wołczyński S. Zaburzenia cyklu miesiączkowego. In: Zgliczyński W [ed.]. Wielka interna: endokrynologia. Part 2. 2nd ed. Medical Tribune Polska. Warszawa 2020, p. 115–132.
8.
Schury MP, Adigun R. Sheehan Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
9.
Chen CF, Liang YC, Tsai MJ, Ou HY. Sheehan’s syndrome presenting with panhypopituitarism and central diabetes insipidus: a case report. BMC Endocr Disord. 2024;24(1):120. doi: 10.1186/s12902-024-01654-w.
10.
Papierska L. Niedoczynność kory nadnerczy. In: Zgliczyński W [ed.]. Wielka interna: endokrynologia. Part 2. 2nd ed. Medical Tribune Polska. Warszawa 2020, p. 22–32.
11.
Bachman EA. Sheehan Syndrome. In: Ferri FF [ed.]. Ferri’s Clinical Advisor 2025: 5 Books in 1. Elsevier. Amsterdam 2025, p. 983 e.18.
12.
Kristjánsdóttir HL, Böðvarsdóttir SP, Sigurjónsdóttir HA. Sheehan’s syndrome – case report and review. [Article in Icelandic]. Laeknabladid. 2010;96(5):348–352. doi: 10.17992/lbl.2010.05.295.
13.
Agrawal P, Garg R, Agrawal M, Singh MK, Verma U, Chauhan R. Sheehan’s Syndrome in India: Clinical Characteristics and Laboratory Evaluation. J Obstet Gynaecol India. 2023;73(Suppl 1):51–55. doi: 10.1007/s13224-023-01801-8.
14.
Zgliczyński W. Niedoczynność przysadki. In: Gajewski P, Jaeschke R [ed.]. Interna Szczeklika. Medycyna Praktyczna. Kraków 2024, p. 1347–1352.
15.
Zgliczyński W. Choroby przysadki a ciąża. In: Zgliczyński W [ed.]. Wielka interna: endokrynologia. Part 2. 2nd ed. Medical Tribune Polska. Warszawa 2020, p. 373–378.
16.
Chrisoulidou A, Boudina M, Karavitaki N, Bili E, Wass J. Pituitary disorders in pregnancy. Hormones (Athens). 2015;14(1):70–80. doi: 10.1007/BF03401382.
17.
Matsuzaki S, Endo M, Ueda Y, Mimura K, Kakigano A, Egawa-Takata T, et al. A case of acute Sheehan’s syndrome and literature review: a rare but life-threatening complication of postpartum hemorrhage. BMC Pregnancy Childbirth. 2017;17(1):188. doi: 10.1186/s12884-017-1380-y.
18.
Jackson FI, Kouba I, Meirowitz N, Keller NA, Bracero LA, Blitz MJ. Association between psychopharmacotherapy and postpartum hemorrhage. AJOG Glob Rep. 2024;4(4):100402. doi: 10.1016/j.xagr.2024.100402.
19.
Javorsky BR, Aron DC, Findling JW, Tyrrell J. Hypothalamus and pituitary gland. In: Gardner DG, Shoback D [ed.]. Greenspan’s Basic & Clinical Endocrinology. McGraw-Hill Education; 2018,
https://accessmedicine.mhmedic... [accesed on 16 February 2025].
20.
Diri H, Sener EF, Bayram F, Tascioglu N, Simsek Y, Dundar M. Etiopathogenesis of Sheehan’s Syndrome: Roles of Coagulation Factors and TNF-Alpha. Int J Endocrinol. 2014;2014:514891. doi: 10.1155/2014/514891.
21.
Johansen LT, Braut GS, Acharya G, Andresen JF, Øian P. How common is substandard obstetric care in adverse events of birth asphyxia, shoulder dystocia and postpartum hemorrhage? Findings from an external inspection of Norwegian maternity units. Acta Obstet Gynecol Scand. 2021;100(1):139–146. doi: 10.1111/aogs.13959.
22.
Ruchała M., Szczepanek-Parulska E. Choroby przysadki. In: Bręborowicz GH, Czajkowski K [ed.]. Położnictwo i ginekologia. Part 1. Wyd. Lekarskie PZWL. Warszawa 2020, p. 346–349.
23.
Di Naro E, Loverro M, Converti I, Loverro MT, Ferrara E, Rapone B. The Effect of Menopause Hypoestrogenism on Osteogenic Differentiation of Periodontal Ligament Cells (PDLC) and Stem Cells (PDLCs): A Systematic Review. Healthcare (Basel). 2021;9(5):572. doi: 10.3390/healthcare9050572.
24.
Kwiatkowski S, Huras H, Fuchs T, Sokołowska M, Oszukowski P, Stojko R, et al. Rekomendacje Polskiego Towarzystwa Ginekologów i Położników: postępowania w przypadku wystąpienia krwotoków okołoporodowych. Ginekol Perinatol Prakt. 2022;7(1):34–45.
25.
Pineyro MM, Diaz L, Guzzetti M, Risso M, Pereda J. Acute Sheehan’s Syndrome Presenting with Hyponatremia Followed by a Spontaneous Pregnancy. Case Rep Endocrinol. 2022;2022:9181365. doi: 10.1155/2022/9181365.
26.
Lu Y, Wei R, Li S, Peng L, Shi Z. Inflammatory Factor Levels and Clinical Characteristics of Mental Disorders in Patients with Sheehan Syndrome. Altern Ther Health Med. 2023;29(2):218–223.
27.
de Silva NL, Galhenage J, Dayabandara M, Somasundaram N. Sheehan Syndrome Presenting with Psychotic Manifestations Mimicking Schizophrenia in a Young Female: A Case Report and Review of the Literature. Case Rep Endocrinol. 2020;2020:8840938. doi: 10.1155/2020/8840938.
28.
Mandal S, Mukhopadhyay P, Ghosh S. Quality of life in Sheehan Syndrome. Indian J Endocrinol Metab. 2022;26(3):282–283. doi: 10.4103/ijem.ijem_100_22.
29.
Jaramillo AM, Gonzalez R. Psychiatric and Neurocognitive Manifestations of Sheehan Syndrome: A Case Report. Prim Care Companion CNS Disord. 2017;19(1). doi: 10.4088/PCC.16l01996.
30.
Mir SA, Shah T, Singh H, Shabir I, Laway BA. Serum lipid and leptin concentrations in patients with Sheehan syndrome. Indian J Endocrinol Metab. 2018;22(4):466–468. doi: 10.4103/ijem.IJEM_23_18.
31.
Laway BA, Baba MS. Sheehan syndrome: Cardiovascular and metabolic comorbidities. Front Endocrinol (Lausanne). 2023;14:1086731. doi: 10.3389/fendo.2023.1086731.
32.
Zhang Y, Chen P, Fang X. Proteomic and metabolomic analysis of GH deficiency-induced NAFLD in hypopituitarism: insights into oxidative stress. Front Endocrinol (Lausanne). 2024;15:1371444. doi: 10.3389/fendo.2024.1371444.
33.
Marek B, Krysiak R, Okopień B. Adrenal disorders in pregnancy. [Article in Polish]. Pol J Endocrinol. 2009;60(4):331–342.
34.
Kilicli F, Dokmetas HS, Acibucu F. Sheehan’s syndrome. Gynecol Endocrinol. 2013;29(4):292–295. doi: 10.3109/09513590.2012.752454.
35.
Auer MK, Stieg MR, Crispin A, Sievers C, Stalla GK, Kopczak A. Primary Empty Sella Syndrome and the Prevalence of Hormonal Dysregulation. Dtsch Arztebl Int. 2018;115(7):99–105. doi: 10.3238/arztebl.2018.0099.
36.
Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome. Growth Horm IGF Res. 2005;15(3):231–237. doi: 10.1016/j.ghir.2005.03.005.
37.
Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53. doi: 10.1016/j.sxmr.2017.02.004.
38.
Urhan E, Karaca Z. Diagnosis of hypoprolactinemia. Rev Endocr Metab Disord. 2024;25(6):985–993. doi: 10.1007/s11154-024-09896-8.
39.
Uzun I, Karaca Z, Hacioğlu A, Unluhizarci K, Kelestimur F. The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions. Pituitary 2024;27(3):277–286. doi: 10.1007/s11102-024-01393-0.